Skinvisible, Inc. (SKVI) stock
Close on Oct 19, 2026Market cap $843.54KP/E –Yield –
Skinvisible, Inc. grew revenue 0.0% to $20.00K over the twelve months to Jun 30, 2026. Free cash flow was -$42.50K. At the latest close the market valued the company at $843.54K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $843.54K
- P/E ratio
- –
- Price to sales
- 42.18
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -5.04%
Fundamentals
- Revenue
- $20.00K
- Net income
- -$1.03M
- EPS, diluted
- -$0.20
- Free cash flow
- -$42.50K
- Book value per share
- -$2.00
- Diluted shares
- 5M
Trading
- Previous close
- $0.16
- Open
- $0.16
- Day's range
- $0.16 – $0.16
- Volume
- 2,470
- Average volume (20 days)
- 1,903
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | SKVI | S&P 500 | Difference | SKVI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.3% | +0.6% | −23.0 pts | ||
| 3 months | -22.3% | +3.4% | −25.7 pts | ||
| Year to date | -32.3% | +13.3% | −45.6 pts | ||
| 1 year | -61.0% | +16.6% | −77.6 pts | ||
| 3 years | +129.6% | +86.4% | +43.2 pts | +31.9% | +23.1% |
| 5 years | +13.7% | +81.9% | −68.2 pts | +2.6% | +12.7% |
| 10 years | -61.5% | +318.9% | −380.3 pts | -9.1% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Skinvisible filed with the SEC as exhibits to Form 8-K or 6-K
About Skinvisible
Pharmaceutical Preparations
Skinvisible, Inc. is a pharmaceutical research and development company that develops polymer delivery systems and topical formulations. Operating through its wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc., the company focuses on its patented polymer delivery system, Invisicare, which bonds active ingredients to the skin without alcohol, silicones, waxes, or organic solvents. Skinvisible formulates topical prescription and over-the-counter products, which it out-licenses globally to pharmaceutical and consumer goods manufacturers and marketers. It also provides formulation co-development and life cycle management services for products coming off patent. Its formulations target dermatology and skincare markets as well as transdermal applications for conditions such as obesity and diabetes.
Company profile, executives and historySkinvisible stock: common questions
What is Skinvisible's stock price?
SKVI closed at $0.16 on Oct 19, 2026, up 0.06% on the day.
What is Skinvisible's market cap?
Skinvisible was worth $843.54K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is SKVI's P/E ratio?
Skinvisible lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.20), so it has no meaningful P/E ratio.
How much revenue does Skinvisible make?
Skinvisible reported revenue of $20.00K for the twelve months to Jun 30, 2026, up 0.0% from a year earlier.
Does Skinvisible pay a dividend?
No. Skinvisible has not paid a cash dividend over the last twelve months.
How has SKVI stock performed over the past year?
Including dividends, SKVI returned -61.0% over the past year, against +16.6% for the S&P 500.
Who are Skinvisible's competitors?
Companies most similar to Skinvisible by business, industry and size include KPRX, BDPT, JUNS, IBO, PRFX.
See a number that looks wrong?